Ticagrelor Versus Clopidogrel in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Systematic review compares ticagrelor and clopidogrel in chronic coronary syndrome, revealing similar outcomes.
Key Points
Ticagrelor shows similar efficacy and safety to clopidogrel in cardiovascular outcomes for chronic coronary syndrome patients undergoing PCI.
Nine randomized controlled trials with 3370 patients were analyzed, indicating uncertain differences in significant outcomes like myocardial infarction and stroke.
The evidence suggests ticagrelor may not significantly affect cardiovascular mortality or adverse events compared to clopidogrel in this patient group.
However, ticagrelor might increase the risk of chest pain/tightness by about 7.5 per 100 patients, highlighting ongoing concerns regarding its safety.